Acute Hemodynamic Responses to Inhaled Nitric Oxide in Patients With Limited Scleroderma and Isolated Pulmonary Hypertension

Author:

Williamson D.J.1,Hayward C.1,Rogers P.1,Wallman L.L.1,Sturgess A.D.1,Penny R.1,Macdonald P.S.1

Affiliation:

1. the Centre for Immunology (D.J.W., L.L.W., R.P.), Department of Cardiology (C.H.), Respiratory Function Laboratory (P.R.), and Cardiopulmonary Transplant Unit (P.S.M.), St. Vincent's Hospital, Darlinghurst, and the Department of Rheumatology (A.D.S.), St. George Hospital, Kogarah, Australia.

Abstract

Background Inhaled nitric oxide (NO) is a selective pulmonary vasodilator that reduces pulmonary vascular resistance (PVR) in patients with primary pulmonary hypertension. Their responses to inhaled NO predict their responses to other vasodilators, such as prostacyclin, and provide an estimate of the “fixed” component of their increased PVR. Some patients with limited cutaneous systemic sclerosis develop isolated pulmonary hypertension with a similar clinical course. Therefore, we have measured the acute hemodynamic response to inhaled NO in such patients. Methods and Results Seven patients were studied during inhalation of increasing concentrations of NO (0 to 80 ppm). Complete hemodynamic data were collected on five patients. They demonstrated a selective, dose-dependent, and rapidly reversible fall in PVR (34%) and mean pulmonary artery pressure (17%). There was a nonsignificant increase in cardiac index but no change in mean arterial pressure or systemic vascular resistance. The mean right atrial pressure fell (27%), but there was no change in pulmonary artery occlusion pressure. Of the seven patients, five responded to inhaled NO (≤40 ppm) with a decrease in total pulmonary resistance of at least 20%. Conclusions Inhaled NO is an effective and selective pulmonary vasodilator in a significant number of patients with pulmonary hypertension associated with limited cutaneous systemic sclerosis. It may be useful in determining the potentially reversible contribution to the increased PVR and should be considered for patients with acute pulmonary vascular crisis.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference41 articles.

1. Lung disease in systemic sclerosis (scleroderma)

2. Lung involvement in Scleroderma

3. Silver R. Pulmonary hypertension secondary to systemic sclerosis (scleroderma). In: Weir SN Archer SL Reeves JT eds. The Diagnosis and Treatment of Pulmonary Hypertension . New York NY: Futura Publishing Inc; 1992:191-207.

4. REVIEW OF UK DATA ON THE RHEUMATIC DISEASES—9

5. Pulmonary hypertension in the crest syndrome variant of systemic sclerosis

Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3